Skip to main content
. 2014 Nov 2;5(24):12877–12890. doi: 10.18632/oncotarget.2657

Table 1. Characteristics of the NSCLC cell lines used in this study.

NSCLC cell line Histology EGFR status KRAS or LKB1 mutation P53 mutation IC50s of Gefitinib (μM)
HCC4006 AD del E746–A750, amplification no no 0.25
NCI-H1975 AD L858R and T790M no R273H >20
HCC95 SCC wild-type no no >20
NCI-H2122 AD wild-type KRAS (G12C), LKB1(P281fs*6) Q16L, C176F >10
NCI-H3122 AD wild-type EML4/ALK (E13;A20) E285V >10

AD, adenocarcinoma; SCC, squamous cell carcinoma.